Youjia Bio-medical and Livzon Pharmaceutical Group Ink Licensing Deal for siRNA Drug
CompanyDeals

Youjia Biomedical and Livzon Pharmaceutical Group Ink Licensing Deal for siRNA Drug

Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care
CompanyDeals

Bayer AG to Acquire HiDoc Technologies and Launch Digital Health App Cara Care

Eli Lilly's Imlunestrant Reduces Disease Progression in ER+/HER2- Advanced Breast Cancer: EMBER-3 Study
CompanyDrug

Eli Lilly’s Imlunestrant Reduces Disease Progression in ER+/HER2- Advanced Breast Cancer: EMBER-3 Study

Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities
Policy / Regulatory

Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities

Fresenius Kabi Ori Biotech CGT manufacturing IRO platform
CompanyDeals

Fresenius Kabi Partners with Ori Biotech to Integrate IRO Platform with Cell Processing Systems

Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024
CompanyDrug

Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024

GSK Enters Multi-Program Partnerships with Relation Therapeutics for Fibrotic Diseases and Osteoarthritis
CompanyDeals

GSK Enters Multi-Program Partnerships with Relation Therapeutics for Fibrotic Diseases and Osteoarthritis

Novartis' Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024
CompanyDrug

Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024

Legend Biotech's Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial
CompanyDrug

Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial

Huadong Medicine's Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment
CompanyDrug

Huadong Medicine’s Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment

IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study
CompanyDrug

IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study

Patronus Biotech's RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study
CompanyDrug

Patronus Biotech’s RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study